PharmiWeb.com - Global Pharma News & Resources
19-Jun-2019

Recombinant Plasma Protein Therapeutics Market Poised to Touch USD 17.1 Bn by 2026

Global Recombinant Plasma Protein Therapeutics Market Size is expected to reach USD 17.1 Billion by 2026 and growing CAGR around 8.3 % during the forecast period.

The global Recombinant Plasma Protein Therapeutics Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2019 to 2026. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2019 to 2026.

Request a Sample Copy of this Research Report athttps://www.acumenresearchandconsulting.com/request-sample/1308

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global Recombinant Plasma Protein Therapeutics Market.

Key Takeaways:

  • What is the market size in 2018 and the growth rate of the global Recombinant Plasma Protein Therapeutics Market?
  • What is the market drivers, restrains, opportunities governing the global Recombinant Plasma Protein Therapeutics Market?
  • Which is the largest and the fastest growing segments in the global Recombinant Plasma Protein Therapeutics Market?
  • Who are the key players operating in the market and their market position?
  • What is the pipeline scenario, drug pricing analysis and technological development in the market?

Market Players:

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market. The Recombinant Plasma Protein Therapeutics Market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are Octapharma, Novo Nordisk A / S, Bayer AG, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharma Group NV, Pfizer Inc., and CSL Limited, Shire (Takeda Pharmaceutical Company Limited) among others.

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1308

The Major Market Segments of GlobalRecombinant Plasma Protein Therapeutics Marketare as below:

Market Segmentation

Market by Drug Class

  • Human C1 Esterase Inhibitor
  • Recombinant Coagulation Factors

Market by Cell Line

  • Chinese Hamster Ovary (CHO) Cell Line
  • Human Embryonic Kidney (HEK) Cell Line
  • Baby Hamster Kidney (BHK) Cell Line
  • Others

Market by Indication

  • Hemophilia B
  • Hemophilia A
  • Von Willebrand Disease

Market, by Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

The market research study on Recombinant Plasma Protein Therapeutics Market (By Drug Class: Human C1 Esterase Inhibitor, Recombinant Coagulation Factors; By Cell Line: Chinese Hamster Ovary (CHO) Cell Line, Human Embryonic Kidney (HEK) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Others; By Indication: Hemophilia B, Hemophilia A, Von Willebrand Disease) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026 offers detailed insights on global Recombinant Plasma Protein Therapeutics market segments with market dynamics and their impact. The report provides insights on global Recombinant Plasma Protein Therapeutics Market by Drug Class, by Cell Line, and major geographic regions. The report also covers basic technology development policies.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Recombinant Plasma Protein Therapeutics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Recombinant Plasma Protein Therapeutics Market By Drug Class
1.2.2.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.2.2. Global Recombinant Plasma Protein Therapeutics Market Revenue Share By Drug Class in 2017
1.2.2.3. Human C1 Esterase Inhibitor
1.2.2.4. Recombinant Coagulation Factors
1.2.2.5. Others
1.2.3. Recombinant Plasma Protein Therapeutics Market By Cell Line
1.2.3.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Cell Line (2015-2026)
1.2.3.2. Chinese Hamster Ovary (CHO) Cell Line
1.2.3.3. Human Embryonic Kidney (HEK) Cell Line
1.2.3.4. Baby Hamster Kidney (BHK) Cell Line
1.2.3.5. Others
1.2.4. Recombinant Plasma Protein Therapeutics Market By Indication
1.2.4.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.4.2. Hemophilia B
1.2.4.3. Hemophilia A
1.2.4.4. Von Willebrand Disease
1.2.4.5. Others
1.2.5. Recombinant Plasma Protein Therapeutics Market by Geography
1.2.5.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017

CHAPTER 4. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY DRUG CLASS

4.1. Global Recombinant Plasma Protein Therapeutics Revenue By Drug Class
4.2. Human C1 Esterase Inhibitor
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Recombinant Coagulation Factors
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Other
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY CELL LINE

5.1. Global Recombinant Plasma Protein Therapeutics Revenue By Cell Line
5.2. Chinese Hamster Ovary (CHO) Cell Line
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Human Embryonic Kidney (HEK) Cell Line
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Baby Hamster Kidney (BHK) Cell Line
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY INDICATION

6.1. Global Recombinant Plasma Protein Therapeutics Revenue By Indication
6.2. Hemophilia B
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Hemophilia A
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Von Willebrand Disease
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

7.1. North America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Recombinant Plasma Protein Therapeutics Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

8.1. Europe Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

9.1. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

10.1. Latin America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

11.1. Middle East Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

12.1. Africa Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Cell Line, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Octapharma
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Novo Nordisk A / S
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Bayer AG
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Bioverativ Therapeutics, Inc. (Sanofi)
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Aptevo Therapeutics
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Pharma Group NV
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Pfizer Inc.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. CSL Limited
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Shire (Takeda Pharmaceutical Company Limited)
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1308

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 19-Jun-2019